Lung Disease - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 48 pages report, published by Global Markets Direct

Keywords : Lung Disease Therapeutic Products under Development, Key Players in Lung Disease Therapeutics, Lung Disease Pipeline Overview, Lung Disease Pipeline, Lung Disease Pipeline Assessment

Report ThumbnailSeptember-2013
Lung Disease - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Lung Disease - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lung Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Disease. Lung Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lung Disease.
- A review of the Lung Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lung Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lung Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lung Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Lung Disease, H2 2013 8
  • Products under Development for Lung Disease - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Products under Investigation by Universities/Institutes, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Discovery and Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 23
  • Assessment by Route of Administration, H2 2013 24
  • Assessment by Stage and Route of Administration, H2 2013 25
  • Assessment by Molecule Type, H2 2013 26
  • Assessment by Stage and Molecule Type, H2 2013 27
  • List of Tables
  • Number of Products Under Development for Lung Disease, H2 2013 8
  • Products under Development for Lung Disease - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 10
  • Number of Products under Investigation by Universities/Institutes, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • Ablynx, H2 2013 16
  • Vectura Group plc, H2 2013 17
  • Pharmaxis Ltd., H2 2013 18
  • Neurim Pharmaceuticals (1991) Ltd., H2 2013 19
  • AGI Therapeutics plc, H2 2013 20
  • Nostrum Pharmaceuticals, LLC, H2 2013 21
  • PharmaIN Corporation, H2 2013 22
  • Assessment by Monotherapy Products, H2 2013 23
  • Assessment by Stage and Route of Administration, H2 2013 25
  • Assessment by Stage and Molecule Type, H2 2013 27
  • Lung Disease Therapeutics - Dormant Products 43
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Lung Disease Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Lung Disease 8
  • Lung Disease Therapeutics under Development by Companies 10
  • Lung Disease Therapeutics under Investigation by Universities/Institutes 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Discovery and Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Lung Disease Therapeutics - Products under Development by Companies 14
  • Lung Disease Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Lung Disease Therapeutics Development 16
  • Ablynx 16
  • Vectura Group plc 17
  • Pharmaxis Ltd. 18
  • Neurim Pharmaceuticals (1991) Ltd. 19
  • AGI Therapeutics plc 20
  • Nostrum Pharmaceuticals, LLC 21
  • PharmaIN Corporation 22
  • Lung Disease - Therapeutics Assessment 23
  • Assessment by Monotherapy Products 23
  • Assessment by Route of Administration 24
  • Assessment by Molecule Type 26
  • Drug Profiles 28
  • Neu-164 - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • VR-461 - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • PXS-4206 - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • AGI-350 - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • cladribine - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • PGC-VIP - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • AO Inhibitors For Lung Disease - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • dapsone - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • Retinoic Acid Receptor Agonists - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • Compounds For Lung And Liver Disease - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • Recombinant Human Follistatin - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • Pulmonary Disease Program 1 - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • Pulmonary Disease Program 2 - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • Ornithine-Substituted ADP-Ribosyl HNP-1 - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • Ornithine-HNP-1 - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • Lung Disease Therapeutics - Dormant Products 43
  • Lung Disease - Product Development Milestones 44
  • Featured News & Press Releases 44
  • Jun 27, 2012: Researchers Provide Further Rationale For Proteo's Elafin Treatment In Newborn Infants 44
  • Mar 05, 2012: Medistem To Begin Clinical Trials Using ERC Stem Cells For Renal, Lung And Peripheral Artery Disease 44
  • Jan 02, 2012: Commonly Used Blood Pressure Drug Prevents Smoking-related Lung Damage In Mice 45
  • Appendix 47
  • Methodology 47
  • Coverage 47
  • Secondary Research 47
  • Primary Research 47
  • Expert Panel Validation 47
  • Contact Us 48
  • Disclaimer 48

Please select a license type

Share

Related Products

Global Markets DirectLung Disease - Pipeline Review, H2 2013Product ThumbnailLung Disease - Pipeline Review, H2 2013, Industry ReportProduct #: 113307
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved